Join
Live feed
·
PRReleasevia Quantisnow
Erasca Inc. logo

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
ERAS· Erasca Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ERAS (Erasca Inc.) and more on Quantisnow.